MALIGNANT B-CELL CD5 MEMBRANE PHENOTYPE AND B-CELL COLONY GROWTH IN-VIVO AND IN-VITRO IN PATIENTS WITH B-CHRONIC LYMPHOCYTIC-LEUKEMIA - ANALYSIS WITH CLINICAL-PARAMETERS

被引：1

作者：

HINGS, I ^{[1
]}

KAY, NE ^{[1
]}

RANHEIM, E ^{[1
]}

SEROOGY, C ^{[1
]}

PARSON, RE ^{[1
]}

机构：

[1] HYBRITECH INC,POB 269006,SAN DIEGO,CA 92196

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 12卷 / 1-2期

关键词：

CD5 B-CELL COLONY GROWTH; B-CLL; CLINICAL PARAMETERS;

D O I：

10.3109/10428199309059572

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic lymphocytic leukemia (CLL), despite an overall good prognosis, has a subgroup of patients with more rapid, aggressive disease. In an attempt to generate additional information about the B cell clones in B-CLL which could be used as predictive parameters, we analysed CD5 membrane phenotype and B cell colony growth in 29 B-CLL patients. CD5, a 67-kd glycoprotein, has been reported to be a consistent feature of the malignant B cell membrane phenotype in CLL. We used an in vitro B cell colony assay to study the in vitro growth, differentiation, and cell surface properties of CLL B cells, Finally, a variety of standard clinical parameters were collated for each patient. Monoclonal antibodies to both CD5 and CD19 (pan B cell marker) were used to perform 2-color flow cytometry on freshly purified CLL B cells and on CLL B cells harvested after 7 days of in vitro culture. We demonstrate here that CLL B cells are heterogeneous with respect to their expression of CD5, and that this expression is not fixed but may vary both in vivo and in vitro. In vitro growth potential, as measured by the B cell colony assay, was also heterogeneous with three subgroups defined as low growth (<10 colonies), intermediate (10-100 colonies) and high growth (>100 colonies). Furthermore a T cell conditioned medium was not found to be a requirement for in vitro colony growth in the majority of CLL B cells. In addition, we evaluated the potential correlation of B cell CD5 phenotype or B cell colony growth on standard clinical parameters. A correlation between high CD5 expression (>85% CD5 positive) and lymphocyte doubling time less than 12 months and treatment within six months was detected. This study emphasizes that additional information regarding the biology of the malignant CLL B cell will generate new parameters that can be used to help predict the clinical course of B-CLL.

引用

页码：59 / 67

页数：9

共 17 条

[1]

Foon K.A., Rai K.R., Gale R.P., Chronic lymphocytic leukemia: New insights into biology and therapy, Ann. Int. Med., 113, pp. 525-539, (1990)

[2]

Kluin-Nelemans J.C., Willemze R., Human B cell colony assays, Blut., 55, pp. 189-198, (1987)

[3]

Dadmarz R., Rabinowe S.N., Cannistra S.A., Association between clonogenic cell growth and clinical risk group in B cell chronic lymphocytic leukemia, Blood, 76, pp. 142-149, (1990)

[4]

Kipps T.J., The CD5 B Cell, Adv. Immunol., 47, pp. 117-185, (1989)

[5]

Freedman A.S., Freedman G., Whitman J., Expression and regulation of CD5 in in vitro activated human B cells, Eur. J. Immunol., 19, pp. 849-855, (1989)

[6]

Bergui L., Tesio L., Schena M., CD5 and CD21 molecules are a functional unit in the cell/substrate adhesion of B-chronic lymphocytic leukemia cells, Eur. J. Immunol., 18, pp. 89-96, (1988)

[7]

Kay N., Perri R., Evidence that large granular lymphocytes from B-CLL patients with hypogammaglobulinemia down-regulate B-Cell immunoglobulin synthesis, Blood, 73, pp. 1016-1019, (1989)

[8]

Daniel W.W., Applied nonparametric statistics, pp. 120-124, (1990)

[9]

Kay N., Peterson L., Heterogeneity of CD5 membrane expression on B-Chronic lymphocytic leukemia cells, Leukemia and Lymphoma, 5, pp. 49-55, (1991)

[10]

Dighiero G., Binet J.-L., Does the CLL B lymphocyte correspond to expansion of an immature B clone or to expansion of a distinct subpopulation of B cells, Blood Cells, 12, pp. 385-397, (1987)

← 1 2 →